Significant Accounting Policies (Details Narrative)
|
3 Months Ended |
6 Months Ended |
12 Months Ended |
|
|
Jun. 30, 2020
USD ($)
Breathalyzers
shares
|
Jun. 30, 2019
USD ($)
Breathalyzers
shares
|
Jun. 30, 2020
USD ($)
Breathalyzers
shares
|
Jun. 30, 2019
USD ($)
Breathalyzers
shares
|
Dec. 31, 2019
USD ($)
Breathalyzers
|
Jan. 02, 2020
USD ($)
|
| Restricted cash |
$ 115,094
|
|
$ 115,094
|
|
$ 115,094
|
|
| Maturities of securities |
|
|
less than one year
|
|
|
|
| Increase in unrealized gain on securities |
201,898
|
$ 18,059
|
|
$ 47,402
|
|
|
| Increase in unrealized loss on securities |
|
|
$ 39,039
|
|
|
|
| Loss on sale of securities |
0
|
543
|
36,714
|
4,258
|
|
|
| Proceeds from sale of marketable securities |
3,572
|
2,307,462
|
502,126
|
1,354,646
|
|
|
| Allowances for doubtful accounts for trade receivables |
1,273
|
|
1,273
|
|
458,902
|
|
| Bad debt expenses |
1,273
|
0
|
1,273
|
4,247
|
|
|
| Impairment of prepaid royalties |
291,442
|
|
291,442
|
|
|
|
| Total revenues |
(1,888)
|
464,513
|
361,627
|
1,076,634
|
1,577,033
|
|
| Depreciation expense |
3,214
|
9,542
|
10,111
|
14,975
|
|
|
| Impairment expense |
18,680
|
0
|
18,680
|
0
|
|
|
| Operating lease, annual rentals |
|
|
$ 132,000
|
|
|
|
| Operating lease description |
|
|
The Company leases its facility in West Deptford, New Jersey (the "Thorofare Facility") under an operating lease ("Thorofare Lease") with annual rentals of $132,000 plus common area maintenance (CAM) charges. The Thorofare Facility houses the Company's office, manufacturing, laboratories and warehouse space. The lease, took effect on January 1, 2008. On January 7, 2013, the Company extended its lease agreement for a term of 7 years, expiring December 31 2019. On November 11, 2019, the Company entered into an extension of the Thorofare Lease, extending the term to December 31, 2021, effective January 1, 2020, and providing for an early termination option of the lease with a 150 day notice period.
|
|
|
|
| Right-of-use asset |
79,942
|
|
$ 79,942
|
|
|
$ 306,706
|
| Operating lease, liability |
80,018
|
|
80,018
|
|
|
|
| Impairment of intangible assets |
149,870
|
|
152,822
|
|
|
|
| Intangible assets |
|
|
|
|
170,423
|
|
| Amortization expense |
8,727
|
10,002
|
17,601
|
20,004
|
|
|
| Accrued for rebates and incentives |
|
|
200
|
|
20,002
|
|
| Rebates recognized during period |
536
|
7,679
|
1,199
|
16,377
|
|
|
| Sales discounts |
10,632
|
7,406
|
$ 11,366
|
20,957
|
|
|
| Income tax examination, likelihood percentage |
|
|
The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement.
|
|
|
|
| Unrecognized tax benefits |
|
|
|
|
|
|
| Income tax benefit |
|
|
|
|
|
|
| Accrued for penalties and interest |
|
|
|
|
|
|
| Shipping and handling cost |
1,511
|
9,511
|
10,568
|
21,997
|
|
|
| Product cost of sales |
377,169
|
219,864
|
550,040
|
465,801
|
|
|
| Net loss attributable to common shareholders |
$ 3,628,131
|
$ 794,891
|
$ 7,166,667
|
$ 1,711,849
|
|
|
| Weighted average basic and diluted common shares outstanding | shares |
5,252,211
|
541,367
|
3,739,529
|
541,000
|
|
|
| Shipping and Handling [Member] |
|
|
|
|
|
|
| Product cost of sales |
$ 5,251
|
$ 15,660
|
$ 17,918
|
$ 27,579
|
|
|
| Patents, Trademarks and Customer Lists [Member] |
|
|
|
|
|
|
| Intangible assets |
$ 3,897,635
|
|
3,897,635
|
|
3,897,635
|
|
| Amortization expense |
|
|
$ 3,897,635
|
|
$ 3,727,212
|
|
| Topic 842 [Member] |
|
|
|
|
|
|
| Right-of-use asset |
|
|
|
|
|
306,706
|
| Operating lease, liability |
|
|
|
|
|
$ 306,706
|
| No Suppliers [Member] |
|
|
|
|
|
|
| Concentration risk percentage |
|
|
10.00%
|
|
10.00%
|
|
| Sales Revenue, Net [Member] | Customer One [Member] |
|
|
|
|
|
|
| Concentration risk percentage |
|
|
58.00%
|
42.00%
|
|
|
| Sales Revenue, Net [Member] | Customer Two [Member] |
|
|
|
|
|
|
| Concentration risk percentage |
|
|
35.00%
|
20.00%
|
|
|
| Sales Revenue, Net [Member] | Customer Three [Member] |
|
|
|
|
|
|
| Concentration risk percentage |
|
|
|
19.00%
|
|
|
| Sales Revenue, Net [Member] | Three Customers [Member] |
|
|
|
|
|
|
| Concentration risk percentage |
|
|
|
81.00%
|
|
|
| Concentration risk, number of customer | Breathalyzers |
|
|
|
3
|
|
|
| Sales Revenue, Net [Member] | Two Customers [Member] |
|
|
|
|
|
|
| Concentration risk percentage |
|
|
93.00%
|
|
|
|
| Concentration risk, number of customer | Breathalyzers |
|
|
2
|
|
|
|
| Trade Receivable [Member] | Customer One [Member] |
|
|
|
|
|
|
| Concentration risk percentage |
|
|
30.00%
|
44.00%
|
30.00%
|
|
| Trade Receivable [Member] | Customer Two [Member] |
|
|
|
|
|
|
| Concentration risk percentage |
|
|
18.00%
|
34.00%
|
18.00%
|
|
| Trade Receivable [Member] | Customer Three [Member] |
|
|
|
|
|
|
| Concentration risk percentage |
|
|
12.00%
|
|
12.00%
|
|
| Trade Receivable [Member] | Two Customers [Member] |
|
|
|
|
|
|
| Concentration risk percentage |
|
|
|
78.00%
|
|
|
| Concentration risk, number of customer | Breathalyzers |
|
|
|
2
|
|
|
| Trade Receivable [Member] | Customer Four [Member] |
|
|
|
|
|
|
| Concentration risk percentage |
|
|
12.00%
|
|
12.00%
|
|
| Trade Receivable [Member] | Customer Five [Member] |
|
|
|
|
|
|
| Concentration risk percentage |
|
|
11.00%
|
|
11.00%
|
|
| Trade Receivable [Member] | Five Customers [Member] |
|
|
|
|
|
|
| Concentration risk percentage |
|
|
83.00%
|
|
83.00%
|
|
| Concentration risk, number of customer | Breathalyzers |
|
|
5
|
|
5
|
|
| Accounts Payable [Member] |
|
|
|
|
|
|
| Concentration risk percentage |
|
|
63.00%
|
63.00%
|
|
|
| Concentration risk, number of supplier | Breathalyzers |
|
|
2
|
2
|
|
|
| Accounts Payable [Member] | Suppliers One [Member] |
|
|
|
|
|
|
| Concentration risk percentage |
37.00%
|
70.00%
|
49.00%
|
49.00%
|
|
|
| Concentration risk, number of supplier | Breathalyzers |
|
|
1
|
|
|
|
| Accounts Payable [Member] | Suppliers Two [Member] |
|
|
|
|
|
|
| Concentration risk percentage |
28.00%
|
11.00%
|
17.00%
|
17.00%
|
|
|
| Accounts Payable [Member] | Supplier Three [Member] |
|
|
|
|
|
|
| Concentration risk percentage |
11.00%
|
|
|
|
|
|
| Accounts Payable [Member] | Three Supplier [Member] |
|
|
|
|
|
|
| Concentration risk percentage |
76.00%
|
|
|
|
|
|
| Concentration risk, number of customer | Breathalyzers |
3
|
|
|
|
|
|
| Accounts Payable [Member] | Two Supplier [Member] |
|
|
|
|
|
|
| Concentration risk percentage |
|
81.00%
|
66.00%
|
|
|
|
| Concentration risk, number of customer | Breathalyzers |
|
2
|
|
|
|
|
| Accounts Payable [Member] | Two Suppliers [Member] |
|
|
|
|
|
|
| Concentration risk percentage |
|
|
|
66.00%
|
|
|
| Minimum [Member] |
|
|
|
|
|
|
| Normal credit terms extended to customers |
|
|
30 days
|
|
|
|
| Maximum [Member] |
|
|
|
|
|
|
| Normal credit terms extended to customers |
|
|
90 days
|
|
|
|